CEDM is a recent development of digital mammography using the intra-venous injection of an iodinated contrast agent in conjunction with mammography examination. Initial clinical experience has shown the ability of CEDM to map the distribution of neo-vasculature induced by cancer using mammography. Moreover, previous studies have shown a superiority of CEDM either for the assessment of the probability of malignancy or for BI-RADS assessment compared to mammography alone. The potential clinical applications are the clarification of mammographically equivocal lesions, the detection of occult lesions on standard mammography, particularly in dense breast, the determination of the extent of disease, the assessment of recurrent disease and the monitoring of the response to chemotherapy. CEDM should result in a simple way to enhance the detection and the characterization of breast lesions.